Antitumor activity of rucaparib plus PLX038A in serous endometrial carcinoma
Collectively, these studies identify a set of genomically characterized PDX models for preclinical testing of potential SEC therapies and a therapeutic combination that warrants further preclinical investigation.
Authors
- Conway Xu
- Yuanhang Liu (ORCID: https://orcid.org/0000-0002-0147-8394)
- Kevin Peterson (ORCID: https://orcid.org/0000-0002-6914-8586)
- Shaun D. Fontaine (ORCID: https://orcid.org/0000-0002-5800-0391)
- Jamie Nadine Bakkum-Gamez (ORCID: https://orcid.org/0000-0001-7018-8625)
- Hunter J. Atkinson
- S. John Weroha
- Valentina Zanfagnin (ORCID: https://orcid.org/0000-0002-7703-7982)
- Gretchen Glaser (ORCID: https://orcid.org/0000-0001-9413-316X)
- Scott H. Kaufmann (ORCID: https://orcid.org/0000-0002-4900-7145)
- Gerardo Colón‐Otero (ORCID: https://orcid.org/0000-0002-9159-2421)
- Daniel V. Santi (ORCID: https://orcid.org/0000-0002-3790-0673)
- Kristina Butler (ORCID: https://orcid.org/0000-0001-5432-5562)
- Erik Jessen (ORCID: https://orcid.org/0000-0001-9851-6897)
- Ann L. Oberg (ORCID: https://orcid.org/0000-0003-2539-9807)
- Sarah Gill (ORCID: https://orcid.org/0000-0003-0149-7672)
- Laura N. Duffield
- Chen Wang (ORCID: https://orcid.org/0000-0001-6461-1271)
- Melissa C. Larson (ORCID: https://orcid.org/0000-0002-5430-8161)
- Yajue Huang
- S.C. Dowdy
- Xiaonan Hou
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- ProLynx (United States) (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1186/s13046-025-03406-7
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novartis Pharmaceuticals Corporation
- National Institutes of Health
- National Cancer Institute